IMPORTANT NOTICE TO SHAREHOLDERS: Brower Piven Notifies Shareholders of Securities Class Action Lawsuit And Encourages Inves...
20 Juillet 2016 - 2:55AM
The securities litigation law firm of Brower Piven, A Professional
Corporation, announces that a class action lawsuit has been
commenced in the United States District Court for the District of
New Jersey on behalf of purchasers of Insmed Incorporated
(Nasdaq:INSM) (“Insmed” or the “Company”) securities during the
period between March 18, 2013 and June 8, 2016, inclusive (the
“Class Period”). Investors who wish to become proactively
involved in the litigation have until September 13, 2016 to seek
appointment as lead plaintiff.
If you wish to choose counsel to represent you
and the Class, you must apply to be appointed lead plaintiff and be
selected by the Court. The lead plaintiff will direct the
litigation and participate in important decisions including whether
to accept a settlement for the Class in the action. The lead
plaintiff will be selected from among applicants claiming the
largest loss from investment in Insmed securities during the Class
Period. Members of the Class will be represented by the lead
plaintiff and counsel chosen by the lead plaintiff. No class
has yet been certified in the above action.
The complaint accuses the defendants of
violations of the Securities Exchange Act of 1934 by virtue of the
defendants’ failure to disclose during the Class Period that the
data on which Insmed’s European marketing authorization application
(“MAA”) relied for Arikayce, was not likely to support approval by
the European Medicines Agency (“EMA”) for the treatment of NTM lung
disease, therefore making Arikayce’s approval by the EMA for the
treatment of NTM lung disease and subsequent commercialization in
Europe less likely and/or imminent than Insmed had led investors to
believe.
According to the complaint, following the June
8, 2016 revelation that Insmed had withdrawn its MAA from the EMA
for Arikayce for the treatment of NTM lung disease with the intent
to resubmit its MAA when clinical data from its ongoing global
phase 3 study becomes available, the value of Insmed shares
declined significantly.
If you have suffered a loss in excess of
$100,000 from investment in Insmed securities purchased on or after
March 18, 2013 and held through the revelation of negative
information during and/or at the end of the Class Period and would
like to learn more about this lawsuit and your ability to
participate as a lead plaintiff, without cost or obligation to you,
please visit our website at
http://www.browerpiven.com/currentsecuritiescases.html. You
may also request more information by contacting Brower Piven either
by email at hoffman@browerpiven.com or by telephone at (410)
415-6616. Brower Piven also encourages anyone with
information regarding the Company’s conduct during the period in
question to contact the firm, including whistleblowers, former
employees, shareholders and others.
Attorneys at Brower Piven have extensive
experience in litigating securities and other class action cases
and have been advocating for the rights of shareholders since the
1980s. If you choose to retain counsel, you may retain Brower
Piven without financial obligation or cost to you, or you may
retain other counsel of your choice. You need take no action
at this time to be a member of the class.
CONTACT: Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
hoffman@browerpiven.com
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024